0 0.5 1 1.5+ All studies 49% 11 1,436 Improvement, Studies, Patients Relative Risk Mortality 61% 5 790 Ventilation 89% 1 49 ICU admission 74% 5 790 Hospitalization 48% 3 301 Recovery 34% 7 938 Cases 93% 3 346 Viral clearance 56% 3 200 RCTs 43% 10 1,323 RCT mortality 61% 5 790 Peer-reviewed 39% 10 1,323 Exc. combined 68% 5 632 Prophylaxis 93% 3 346 Early 32% 4 352 Late 34% 4 738 Quercetin for COVID-19 c19early.org October 2023 after exclusions Favorsquercetin Favorscontrol